Market revenue in 2023 | USD 289.2 million |
Market revenue in 2030 | USD 706.8 million |
Growth rate | 13.6% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.89% in 2023. Horizon Databook has segmented the UK immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Key players engaged in the development of biomarkers and partnerships between international companies are expected to fuel market growth. Government initiatives such as investments in R&D of high-quality, cost-effective, standardized products for diagnosis and treatment of neurodegenerative disease research.
For instance, in November 2021, the Department of Health and Social Care announced an investment of USD 456.62 million in neurodegenerative research in the UK. Moreover, the use of clinical data informatics platforms by productive research organizations is anticipated to propel market growth in the coming years.
An increase in the number of initiatives being undertaken by private and public organizations to fund R&D for biomarkers is anticipated to fuel market growth. For instance, the UK Biobank, a registered charity, aims to improve the management of diseases such as dementia, stroke, and heart disease.
Horizon Databook provides a detailed overview of country-level data and insights on the UK immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into UK immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account